Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718734 | 0.85 | KCNH2 (0.55) | KCNH2GRM5 | |
| SCHEMBL27783146 | 0.83 | GRM5 (0.55) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL15540865 | 0.83 | CA12 (0.50) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL22203008 | 0.83 | GRM5 (0.44) | KCNH2GRM5 | |
| SCHEMBL211397 | 0.79 | — | — | |
| Bromide SCHEMBL28158133 | 0.77 | APP (0.61) | APPKCNH2MAPTGRM5CA12 | |
| SCHEMBL15402202 | 0.77 | APP (0.61) | APPKCNH2MAPTGRM5CA12 | |
| SCHEMBL718732 | 0.74 | APP (0.42) | APPKCNH2MAPT | |
| SCHEMBL6364777 | 0.73 | APP (0.75) | APPKCNH2MAPTGRM5CA12 | |
| SCHEMBL719191 | 0.71 | APP (0.38) | APPKCNH2MAPTGRM5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445141-B2 | Sulfonic acid group-containing polymer, method for producing the same, resin composition containing such sulfonic acid group-containing polymer, polymer electrolyte membrane, polymer electrolyte membrane/electrode assembly, and fuel cell | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8216727-B2 | Aromatic hydrocarbon based proton exchange membrane and direct methanol fuel cell using same | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20120052411-A9 | AROMATIC HYDROCARBON BASED PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20090075147-A1 | Sulfonic acid group-containing polymer, method for producing the same, resin composition containing such sulfonic acid group-containing polymer, polymer electrolyte membrane, polymer electrolyte membrane/electrode assembly, and fuel cell | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1889863-A1 | SULFONIC ACID GROUP-CONTAINING POLYMER, METHOD FOR PRODUCING SAME, RESIN COMPOSITION CONTAINING SUCH SULFONIC ACID GROUP-CONTAINING POLYMER, POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE/ELECTRODE ASSEMBLY, AND FUEL CELL | Toyo Boseki Kabushiki Kasisha (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070207361-A1 | AROMATIC HYDROCARBON BASED PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1826846-A1 | AROMATIC HYDROCARBON-BASE PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | Toyo Boseki Kabushiki Kasisha (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7220745-B2 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1641452-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | Rigel Pharmaceuticals (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1620412-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2004-12-16 | — | — | US | disclosed |
| WO-2004103366-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | RIGEL PHARMACEUTICALS (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | HAVCR2, PCNA, HCCS | APP 4434/4885KCNH2 4714/4885MAPT 4317/4885 |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | HAVCR2, PCNA, HCCS | APP 3571/4885KCNH2 4468/4885MAPT 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.